

Financial Tear Sheet

Corporate Profile

MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.

We process human placental tissue utilizing our proprietary PURION® Process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. We dry preserves human amniotic membrane tissue, resulting in minimally manipulated tissue products that address numerous serious unmet medical needs requiring tissue regeneration or healing inside and outside the body.

MiMedx has supplied **over 1 Million** placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Our patent-protected PURION® Process is the foundation of our AmnioFix® and EpiFix® products that serve to regenerate damaged or diseased tissues by delivering human extracellular matrix components, essential growth factors, and specialized mediating cytokines. AmnioFix®, EpiFix® and AmnioFill™ modulate inflammation, reduce scar tissue formation, and enhance healing.

Additional MiMedx products include: EpiCord™ and AmnioCord™, derived from the umbilical cord; OrthoFlo, an amniotic fluid derived allograft; CollaFix™, our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. placental Collagen brands; AlloBurn™, a skin product derived from human skin designed for the treatment of burns brand; and Physio®, a unique bone grafting material comprised of 100% bone tissue with no added carrier.

Primary IR Contact

Robert P. Borchert
Vice President, Investor
Relations
Phone: 770.651.9383
E-mail:
rborchert@mimedx.com

Stock Performance

MDXG (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	E
Price	\$7.22
Change (%)	▼ 0.14 (1.90%)
Volume	2,487,931
52 Week Low	\$6.05
Market Cap	\$801,671,783
Rolling EPS	0.31
PE Ratio	23.29
Shares Outstanding	111,034,873

Data as of Mar 19, 2018 4:00 p.m. ET



Recent Headlines & Events

Mar 15, 2018 - 10:40 a.m.

[MiMedx Announces Expectation to Exceed the \\$92 Million Top End of First Quarter Revenue Guidance](#)

Mar 09, 2018 - 12:45 p.m.

[AmnioFix® Injectable Granted Regenerative Medicine Advanced Therapy \(RMAT\) Designation by the FDA for the Treatment of Osteoarthritis of the Knee](#)

Mar 02, 2018 - 5:51 p.m.

[MiMedx Receives Notice of Filing Delinquency from NASDAQ](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
Mar 15, 2018	8-K
Mar 05, 2018	8-K
Mar 02, 2018	NT 10-K
Feb 28, 2018	4

Corporate Governance

[Parker "Pete" H. Petit](#)

Chairman and Chief Executive Officer

[William C. Taylor](#)

President and Chief Operating Officer

[Michael J. Senken](#)

Chief Financial Officer

[Alexandra Haden](#)

General Counsel and Secretary

[Christopher M. Cashman](#)

EVP and Chief Commercialization Officer

[Deborah L. Dean](#)

Executive Vice President

[Thornton A. Kuntz](#)

Senior Vice President of Administration

[Michael W. Carlton](#)

Senior Vice President of Global Sales

[Marlene M. DeSimone](#)

Senior Vice President of Corporate Strategic Development

[Dr. I. Mark Landy](#)

Senior Vice President Strategic Initiatives

[Gloria Matthews, DVM, PhD, DACVS](#)

Senior Vice President, Research and Development

[Rebecca J. C. Brown, Ph.D.](#)

Vice President of Product Development

[Frank Burrows](#)

Vice President of Clinical and Scientific Liaison

[Donald E. Fetterolf, M.D.,FACP](#)

Chief Medical Officer

[Thomas J. Koob, PhD](#)

Chief Scientific Officer

[David H. Mason, Jr., M.D.](#)

Vice President of Medical Affairs for Clinical Practice

[Randall Spencer](#)

Vice President of Clinical Innovation

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed